{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:34:56Z","timestamp":1773059696738,"version":"3.50.1"},"reference-count":88,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The urocortins (Ucns) belong to the corticotropin-releasing factor (CRF) family of peptides and have multiple effects within the central nervous and the cardiovascular systems. With growing evidence indicating significant cardioprotective properties and cardiovascular actions of these peptides, the question arises as to whether the plasma profiles of the Ucns are altered in pathologic settings. While reports have shown conflicting results and findings have not been corroborated in multiple independent cohorts, it seems likely that plasma Ucn concentrations are elevated in multiple cardiovascular conditions. The degree of increase and accurate determination of circulating values of the Ucns requires further validation.<\/jats:p>","DOI":"10.1042\/cs20210732","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T08:21:19Z","timestamp":1640247679000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urocortins as biomarkers in cardiovascular disease"],"prefix":"10.1042","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-9946","authenticated-orcid":false,"given":"In\u00eas","family":"Vasconcelos","sequence":"first","affiliation":[{"name":"Department of Surgery and Physiology, Cardiovascular Research and Development Center - UnIC, Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, Porto 4200-319, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-436X","authenticated-orcid":false,"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[{"name":"Department of Surgery and Physiology, Cardiovascular Research and Development Center - UnIC, Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, Porto 4200-319, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-5979","authenticated-orcid":false,"given":"Miriam\u00a0T.","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-3596","authenticated-orcid":false,"given":"Adelino\u00a0F.","family":"Leite-Moreira","sequence":"additional","affiliation":[{"name":"Department of Surgery and Physiology, Cardiovascular Research and Development Center - UnIC, Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, Porto 4200-319, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-3886","authenticated-orcid":false,"given":"Ana\u00a0Patr\u00edcia","family":"Fontes-Sousa","sequence":"additional","affiliation":[{"name":"Departamento de Imuno-Fisiologia e Farmacologia, Centro de Investiga\u00e7\u00e3o Farmacol\u00f3gica e Inova\u00e7\u00e3o Medicamentosa (MedInUP), ICBAS - Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, Rua Jorge de Viterbo Ferreira 228, Porto 4050-313, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-3776","authenticated-orcid":false,"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[{"name":"Department of Surgery and Physiology, Cardiovascular Research and Development Center - UnIC, Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, Porto 4200-319, Portugal"},{"name":"Faculty of Nutrition and Food Sciences, University of Porto, Rua do Campo Alegre, Porto 823 4150-180, Portugal"}]}],"member":"288","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"2021122308205907300_B1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1210\/endo.137.5.8612563","article-title":"Cloning and characterization of human urocortin","volume":"137","author":"Donaldson","year":"1996","journal-title":"Endocrinology"},{"key":"2021122308205907300_B2","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1073\/pnas.121165198","article-title":"Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor","volume":"98","author":"Lewis","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122308205907300_B3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1073\/pnas.051626398","article-title":"Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors","volume":"98","author":"Reyes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122308205907300_B4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/378287a0","article-title":"Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor","volume":"378","author":"Vaughan","year":"1995","journal-title":"Nature"},{"key":"2021122308205907300_B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1124\/pr.55.1.3","article-title":"International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands","volume":"55","author":"Hauger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"2021122308205907300_B6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/10253890802057221","article-title":"Diurnal expression of period 2 and urocortin 1 in neurones of the non-preganglionic Edinger-Westphal nucleus in the rat","volume":"12","author":"Gaszner","year":"2009","journal-title":"Stress"},{"key":"2021122308205907300_B7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1210\/er.2005-0034","article-title":"The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology","volume":"27","author":"Hillhouse","year":"2006","journal-title":"Endocr. Rev."},{"key":"2021122308205907300_B8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1210\/jc.2003-031663","article-title":"Expression of urocortin III\/stresscopin in human heart and kidney","volume":"89","author":"Takahashi","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021122308205907300_B9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1042\/CS20050079","article-title":"Effect of urocortin 1 infusion in humans with stable congestive cardiac failure","volume":"109","author":"Davis","year":"2005","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021122308205907300_B10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jacc.2006.09.035","article-title":"Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses","volume":"49","author":"Davis","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021122308205907300_B11","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/j.1476-5381.2012.01904.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep","volume":"166","author":"Patel","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"2021122308205907300_B12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.drudis.2015.02.012","article-title":"Urocortin 2 in cardiovascular health and disease","volume":"20","author":"Ad\u00e3o","year":"2015","journal-title":"Drug Discov. Today"},{"key":"2021122308205907300_B13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1073\/pnas.92.3.836","article-title":"Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain","volume":"92","author":"Lovenberg","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122308205907300_B14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0167-0115(00)00180-4","article-title":"The neurobiology of urocortin","volume":"93","author":"Skelton","year":"2000","journal-title":"Regul. Pept."},{"key":"2021122308205907300_B15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1210\/jcem.87.1.8160","article-title":"Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart","volume":"87","author":"Kimura","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021122308205907300_B16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrn.2016.94","article-title":"Region-specific roles of the corticotropin-releasing factor-urocortin system in stress","volume":"17","author":"Henckens","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"2021122308205907300_B17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1253\/circj.CJ-18-0428","article-title":"Corticotropin-releasing hormone family and their receptors in the cardiovascular system","volume":"83","author":"Takefuji","year":"2019","journal-title":"Circ. J."},{"key":"2021122308205907300_B18","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1210\/endo.136.9.7544278","article-title":"CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues","volume":"136","author":"Lovenberg","year":"1995","journal-title":"Endocrinology"},{"key":"2021122308205907300_B19","first-page":"1077","article-title":"Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor","volume":"12","author":"Kostich","year":"1998","journal-title":"Mol. Endocrinol."},{"key":"2021122308205907300_B20","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1073\/pnas.92.7.2969","article-title":"Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart","volume":"92","author":"Perrin","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122308205907300_B21","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1210\/mend.11.13.0034","article-title":"Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors","volume":"11","author":"Liaw","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"2021122308205907300_B22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13028-019-0480-2","article-title":"Urocortins in the mammalian endocrine system","volume":"61","author":"Squillacioti","year":"2019","journal-title":"Acta Vet. Scand."},{"key":"2021122308205907300_B23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.peptides.2005.12.010","article-title":"Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failure","volume":"27","author":"Charles","year":"2006","journal-title":"Peptides"},{"key":"2021122308205907300_B24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0143-4179(98)90033-6","article-title":"Expression and protective effects of urocortin in cardiac myocytes","volume":"32","author":"Okosi","year":"1998","journal-title":"Neuropeptides"},{"key":"2021122308205907300_B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1677\/jme.0.0250043","article-title":"mRNA expression profiles for corticotrophin-releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues","volume":"25","author":"Baigent","year":"2000","journal-title":"J. Mol. Endocrinol."},{"key":"2021122308205907300_B26","doi-asserted-by":"publisher","first-page":"H3031","DOI":"10.1152\/ajpheart.2000.279.6.H3031","article-title":"Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart","volume":"279","author":"Nishikimi","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021122308205907300_B27","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1210\/en.2016-1448","article-title":"Cardiac CRFR1 expression is elevated in human heart failure and modulated by genetic variation and alternative splicing","volume":"157","author":"Pilbrow","year":"2016","journal-title":"Endocrinology"},{"key":"2021122308205907300_B28","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1152\/ajpregu.00045.2017","article-title":"CRF and urocortin 3 protect the heart from hypoxia\/reoxygenation-induced apoptosis in zebrafish","volume":"313","author":"Williams","year":"2017","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021122308205907300_B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1023\/A:1025551305777","article-title":"Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases","volume":"252","author":"Ikeda","year":"2003","journal-title":"Mol. Cell. Biochem."},{"key":"2021122308205907300_B30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1152\/physiologyonline.2000.15.5.264","article-title":"Urocortin: a novel player in cardiac control","volume":"15","author":"Parkes","year":"2000","journal-title":"News Physiol. Sci."},{"key":"2021122308205907300_B31","doi-asserted-by":"publisher","first-page":"H2115","DOI":"10.1152\/ajpheart.1997.272.5.H2115","article-title":"Cardiac inotropic actions of urocortin in conscious sheep","volume":"272","author":"Parkes","year":"1997","journal-title":"Am. J. Physiol."},{"key":"2021122308205907300_B32","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0735-1097(02)02170-8","article-title":"Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep","volume":"40","author":"Rademaker","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021122308205907300_B33","first-page":"257","article-title":"Urocortin and cardiovascular protection","volume":"25","author":"Huang","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"2021122308205907300_B34","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2003-031231","article-title":"Urocortin-1 infusion in normal humans","volume":"89","author":"Davis","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021122308205907300_B35","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1093\/eurheartj\/ehm340","article-title":"Urocortin 2 infusion in human heart failure","volume":"28","author":"Davis","year":"2007","journal-title":"Eur. Heart J."},{"key":"2021122308205907300_B36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jchf.2013.07.003","article-title":"Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)","volume":"1","author":"Chan","year":"2013","journal-title":"JACC Heart Fail."},{"key":"2021122308205907300_B37","doi-asserted-by":"publisher","first-page":"e004267","DOI":"10.1161\/JAHA.112.004267","article-title":"Vascular effects of urocortins 2 and 3 in healthy volunteers","volume":"2","author":"Venkatasubramanian","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"2021122308205907300_B38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/bcp.13033","article-title":"Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure","volume":"82","author":"Stirrat","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021122308205907300_B39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/eurjhf\/hft023","article-title":"Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction","volume":"15","author":"Gheorghiade","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"2021122308205907300_B40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.hfc.2009.04.011","article-title":"What we may expect from biomarkers in heart failure","volume":"5","author":"Richards","year":"2009","journal-title":"Heart Fail Clin."},{"key":"2021122308205907300_B41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"2021122308205907300_B42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1042\/CS20030311","article-title":"Plasma urocortin in human systolic heart failure","volume":"106","author":"Ng","year":"2004","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021122308205907300_B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/CIRCHEARTFAILURE.108.840207","article-title":"Plasma urocortin 1 in human heart failure","volume":"2","author":"Wright","year":"2009","journal-title":"Circ. Heart Fail."},{"key":"2021122308205907300_B44","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.peptides.2009.11.023","article-title":"Circulating levels of stress associated peptide Urocortin in heart failure patients","volume":"31","author":"Gruson","year":"2010","journal-title":"Peptides"},{"key":"2021122308205907300_B45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.5603\/KP.a2013.0353","article-title":"Evaluation of the clinical utility of urocortin 1 in systolic heart failure","volume":"72","author":"Yildirim","year":"2014","journal-title":"Kardiol. Pol."},{"key":"2021122308205907300_B46","first-page":"184","article-title":"The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure","volume":"17","author":"Yildirim","year":"2017","journal-title":"Anatol. J. Cardiol."},{"key":"2021122308205907300_B47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10557-019-06895-9","article-title":"Cardiovascular effects of Urocortin-2: pathophysiological mechanisms and therapeutic potential","volume":"33","author":"Monteiro-Pinto","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021122308205907300_B48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cardfail.2010.03.011","article-title":"Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure","volume":"16","author":"Tang","year":"2010","journal-title":"J. Card. Fail."},{"key":"2021122308205907300_B49","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1373\/clinchem.2015.252932","article-title":"High-sensitivity sandwich ELISA for plasma NT-proUcn2: plasma concentrations and relationship to mortality in heart failure","volume":"62","author":"Liew","year":"2016","journal-title":"Clin. Chem."},{"key":"2021122308205907300_B50","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1084\/jem.20161924","article-title":"Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction","volume":"214","author":"Tsuda","year":"2017","journal-title":"J. Exp. Med."},{"key":"2021122308205907300_B51","doi-asserted-by":"publisher","first-page":"100860","DOI":"10.1016\/j.cpcardiol.2021.100860","article-title":"Urocortin-2 in acute heart failure: role as a marker of volume overload and pulmonary hypertension","author":"Pintalhao","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"2021122308205907300_B52","first-page":"2","article-title":"Serum Urocortin-2 is associated with volume overload and pulmonary hypertension in acute heart failure","volume":"138","author":"Pintalhao","year":"2018","journal-title":"Circulation"},{"key":"2021122308205907300_B53","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.febslet.2008.02.035","article-title":"Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia\/reperfusion injury","volume":"582","author":"Knight","year":"2008","journal-title":"FEBS Lett."},{"key":"2021122308205907300_B54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2362.2005.01466.x","article-title":"Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept","volume":"35","author":"Ilva","year":"2005","journal-title":"Eur. J. Clin. Invest."},{"key":"2021122308205907300_B55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1253\/circj.CJ-08-0668","article-title":"Elevation of plasma granzyme B levels after acute myocardial infarction","volume":"73","author":"Kondo","year":"2009","journal-title":"Circ. J."},{"key":"2021122308205907300_B56","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.ehj.2004.04.026","article-title":"Role and importance of biochemical markers in clinical cardiology","volume":"25","author":"Panteghini","year":"2004","journal-title":"Eur. Heart J."},{"key":"2021122308205907300_B57","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1161\/01.CIR.0000015464.18023.0A","article-title":"Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide","volume":"105","author":"Sabatine","year":"2002","journal-title":"Circulation"},{"key":"2021122308205907300_B58","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1365-2362.2010.02343.x","article-title":"Plasma urocortin in acute myocardial infarction patients","volume":"40","author":"Phrommintikul","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"2021122308205907300_B59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"2021122308205907300_B60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40292-019-00357-x","article-title":"Evaluation of serum urocortin 2 levels in patients with hypertension","volume":"27","author":"Aslan","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"2021122308205907300_B61","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0895-7061(01)01289-4","article-title":"Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients","volume":"14","author":"Cipriano","year":"2001","journal-title":"Am. J. Hypertens."},{"key":"2021122308205907300_B62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.26402\/jpp.2019.2.15","article-title":"Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers","volume":"70","author":"Walczewska","year":"2019","journal-title":"J. Physiol. Pharmacol."},{"key":"2021122308205907300_B63","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1210\/jc.83.12.4510","article-title":"Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro","volume":"83","author":"Leitch","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021122308205907300_B64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jsgi.2004.11.002","article-title":"Reduced maternal plasma urocortin concentrations and impaired uterine artery blood flow at human mid pregnancy","volume":"12","author":"Florio","year":"2005","journal-title":"J. Soc. Gynecol. Investig."},{"key":"2021122308205907300_B65","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.7863\/jum.2010.29.7.1103","article-title":"Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension?","volume":"29","author":"Espinoza","year":"2010","journal-title":"J. Ultrasound Med."},{"key":"2021122308205907300_B66","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1097\/01.hjh.0000242408.65783.b2","article-title":"High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension","volume":"24","author":"Florio","year":"2006","journal-title":"J. Hypertens."},{"key":"2021122308205907300_B67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(00)03577-7","article-title":"Pathogenesis and genetics of pre-eclampsia","volume":"357","author":"Roberts","year":"2001","journal-title":"Lancet"},{"key":"2021122308205907300_B68","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/fn.85.3.F170","article-title":"The relation between pre-eclampsia at term and neonatal encephalopathy","volume":"85","author":"Impey","year":"2001","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"2021122308205907300_B69","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/j.1476-5381.2009.00210.x","article-title":"Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors","volume":"157","author":"Xu","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"2021122308205907300_B70","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1210\/en.2013-1572","article-title":"Sex difference in urocortin production is contributory to the gender disparity in a rat model of vasculitis induced by sodium laurate","volume":"154","author":"Wan","year":"2013","journal-title":"Endocrinology"},{"key":"2021122308205907300_B71","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5152\/akd.2012.036","article-title":"Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: an observational study","volume":"12","author":"Topal","year":"2012","journal-title":"Anadolu Kardiyol. Derg."},{"key":"2021122308205907300_B72","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Adao","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"2021122308205907300_B73","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1042\/CS20130425","article-title":"Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2","volume":"126","author":"Emeto","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021122308205907300_B74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.acvd.2016.03.004","article-title":"Pulmonary arterial hypertension: basic knowledge for clinicians","volume":"109","author":"Santos-Ribeiro","year":"2016","journal-title":"Arch. Cardiovasc. Dis."},{"key":"2021122308205907300_B75","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cpcardiol.2010.08.004","article-title":"Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects","volume":"35","author":"Moxon","year":"2010","journal-title":"Curr. Probl. Cardiol."},{"key":"2021122308205907300_B76","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1024\/0301-1526\/a000371","article-title":"Thromboangiitis obliterans (Buerger\u2019s disease)","volume":"43","author":"Klein-Weigel","year":"2014","journal-title":"Vasa"},{"key":"2021122308205907300_B77","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fendo.2011.00065","article-title":"A role for the androgen metabolite, 5alpha androstane 3beta, 17beta diol (3beta-diol) in the regulation of the hypothalamo-pituitary-adrenal axis","volume":"2","author":"Handa","year":"2011","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021122308205907300_B78","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/1753-0407.13020","article-title":"Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus","volume":"12","author":"Alarslan","year":"2020","journal-title":"J. Diabetes"},{"key":"2021122308205907300_B79","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1161\/01.CIR.96.9.3248","article-title":"Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association","volume":"96","author":"Eckel","year":"1997","journal-title":"Circulation"},{"key":"2021122308205907300_B80","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fendo.2019.00762","article-title":"Urocortin 3 levels are impaired in overweight humans with and without type 2 diabetes and modulated by exercise","volume":"10","author":"Kavalakatt","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021122308205907300_B81","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1073\/pnas.0611641104","article-title":"Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis","volume":"104","author":"Li","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021122308205907300_B82","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1007\/s00125-011-2205-6","article-title":"Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet","volume":"54","author":"Jamieson","year":"2011","journal-title":"Diabetologia"},{"key":"2021122308205907300_B83","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nm.3872","article-title":"Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion","volume":"21","author":"van der Meulen","year":"2015","journal-title":"Nat. Med."},{"key":"2021122308205907300_B84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.hfc.2011.11.005","article-title":"Biomarkers","volume":"8","author":"Florea","year":"2012","journal-title":"Heart Fail Clin."},{"key":"2021122308205907300_B85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10741-008-9123-9","article-title":"Biomarkers in heart failure: a clinical review","volume":"15","author":"Rocchiccioli","year":"2010","journal-title":"Heart Fail. Rev."},{"key":"2021122308205907300_B86","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2017.09.003","article-title":"Urocortins: actions in health and heart failure","volume":"474","author":"Rademaker","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"2021122308205907300_B87","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4155\/bio-2018-0061","article-title":"Clinical biomarker validation","volume":"10","author":"Allinson","year":"2018","journal-title":"Bioanalysis"},{"key":"2021122308205907300_B88","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/aps.2018.29","article-title":"Multiplex biomarker approach to cardiovascular diseases","volume":"39","author":"Adamcova","year":"2018","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/136\/1\/1\/927051\/cs-2021-0732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/136\/1\/1\/927051\/cs-2021-0732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T08:21:29Z","timestamp":1640247689000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/136\/1\/1\/230556\/Urocortins-as-biomarkers-in-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,14]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20210732","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,12,23]]}}}